AT-527, a Double Prodrug of a Guanosine Nucleotide Analog, Is a Potent Inhibitor of SARS-CoV-2 <i>In Vitro</i> and a Promising Oral Antiviral for Treatment of COVID-19
Steven S. Good, Jonna B. Westover, Kie Hoon Jung, Xiao-Jian Zhou, Adel Moussa, Paolo La Colla, Gabriella Collu, Bruno Canard, Jean‐Pierre Sommadossi
Abstract
The impact of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), the causative agent of COVID-19, is global and unprecedented. Although remdesivir has recently been approved by the FDA to treat SARS-CoV-2 infection, no oral antiviral is available for outpatient treatment.
Topics & Concepts
ProdrugCoronavirus disease 2019 (COVID-19)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)GuanosineMedicineVirology2019-20 coronavirus outbreakPharmacologyCoronavirusIn vitroBiologyInternal medicineInfectious disease (medical specialty)DiseaseBiochemistryOutbreakSARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research StudiesCalcium signaling and nucleotide metabolism